Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Essential Therapeutics (ETRX) formerly Microcide (MCDE -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (227)	11/22/1999 8:54:00 AM
From: WTDEC	Respond to of 415

Monday November 22, 6:00 am Eastern Time Company Press Release SOURCE: Microcide Pharmaceuticals, Inc. Microcide Pharmaceuticals Announces Phase I Clinical Trials Underway With RWJ-54428, a Novel Cephalosporin Antibiotic Receipt of Milestone Payment From R. W. Johnson Pharmaceutical Research Institute MOUNTAIN VIEW, Calif., Nov. 22 /PRNewswire/ -- Microcide Pharmaceuticals, Inc. (Nasdaq: MCDE - news) today announced commencement of Phase I clinical trials of the antibiotic RWJ-54428, a novel member of the cephalosporin class first synthesized at Microcide as MC-02,479. With entry into Phase I, Microcide will receive a significant milestone payment from the R. W. Johnson Pharmaceutical Research Institute (RWJPRI), a subsidiary of Johnson & Johnson (NYSE: JNJ - news). ``We're pleased to have advanced this compound, which is so well equipped to treat resistant infections, into the clinic with our colleagues at RWJPRI,' said Jim Rurka, President & CEO of Microcide. ``For Microcide, this is our first antibiotic discovery to reach clinical trials, so it's an important milestone event for the Company, and we're proud to have achieved it.' biz.yahoo.com